Quick Answer
Acumen Pharmaceuticals, Inc. reported Stockholders Equity of $70.43 million for the year ending 2025.
- Acumen Pharmaceuticals, Inc. showed a decrease of -61.3% in Stockholders Equity from 2024 to 2025.
- This data is from Acumen Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$13.43 million | Q2 2020: -$15.42 million | Q3 2020: -$17.87 million | Q1 2021: -$45.46 million | Q2 2021: -$106.08 million | Q3 2021: $233.36 million | Q1 2022: $216.09 million | Q2 2022: $206.52 million | Q3 2022: $196.65 million | Q1 2023: $179.09 million | Q2 2023: $168.87 million | Q3 2023: $280.27 million | Q1 2024: $262.03 million | Q2 2024: $243.95 million | Q3 2024: $217.20 million | Q1 2025: $155.52 million | Q2 2025: $117.08 million | Q3 2025: $93.17 million.
- Over the full 7 years of available data (2019 to 2025), Acumen Pharmaceuticals, Inc.'s Stockholders Equity has grown by 716.7%.
- Historical annual values: Fiscal year 2025: $70.43 million | Fiscal year 2024: $181.82 million | Fiscal year 2023: $266.97 million | Fiscal year 2022: $188.78 million | Fiscal year 2021: $225.18 million | Fiscal year 2020: -$18.59 million | Fiscal year 2019: -$11.42 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: